Biosimilars vs originators: Are they the same?

[1]  A. Ramanan,et al.  Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis , 2019, Pediatric Rheumatology.

[2]  P. Sarzi-Puttini,et al.  The therapeutic journey of biologic agents: There will be an end? , 2019, Pharmacological research.

[3]  P. Sarzi-Puttini,et al.  Systemic rheumatic diseases: From biological agents to small molecules. , 2019, Autoimmunity reviews.

[4]  A. Ceribelli,et al.  Biosimilars: New guns for the treatment of rheumatologic patients? , 2019, Beyond Rheumatology.

[5]  Changsoo Lee,et al.  Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira®. , 2019, Biologicals : journal of the International Association of Biological Standardization.

[6]  Stanley B. Cohen,et al.  A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy , 2018, Arthritis Research & Therapy.

[7]  D. Wendling,et al.  Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI). , 2018, Joint, bone, spine : revue du rhumatisme.

[8]  P. Sarzi-Puttini,et al.  TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? , 2017, Autoimmunity reviews.

[9]  D. Thaçi,et al.  Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque‐type psoriasis: 30‐week results from the phase 3, confirmatory EGALITY study , 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  F. Breedveld,et al.  Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases , 2017, Annals of the rheumatic diseases.

[11]  Y. Shoenfeld,et al.  International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unm , 2017, Autoimmunity reviews.

[12]  P. Emery,et al.  Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4 , 2017, Annals of the Rheumatic Diseases.

[13]  A. Vulto,et al.  The process defines the product: what really matters in biosimilar design and production? , 2017, Rheumatology.

[14]  J. Skoupá,et al.  Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries , 2017, Front. Pharmacol..

[15]  R. Moots,et al.  Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician , 2017, Current Rheumatology Reports.

[16]  Inge Christoffer Olsen,et al.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial , 2017, The Lancet.

[17]  B. Strober,et al.  Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double‐blind, multicenter, phase III study , 2017, Journal of the American Academy of Dermatology.

[18]  G. Woollett,et al.  A ‘Global Reference’ Comparator for Biosimilar Development , 2017, BioDrugs.

[19]  A. Loft,et al.  A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry , 2017, Annals of the rheumatic diseases.

[20]  L. Berrino,et al.  Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achieve. , 2017, Pharmacological research.

[21]  R. Danesi,et al.  The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects , 2017, Drugs.

[22]  B. Soos,et al.  Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data , 2017, ClinicoEconomics and outcomes research : CEOR.

[23]  N. Nikolov,et al.  An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology , 2017, Nature Reviews Rheumatology.

[24]  P. Miranda,et al.  Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study , 2016, Annals of the rheumatic diseases.

[25]  P. Miranda,et al.  Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study , 2016, Annals of the rheumatic diseases.

[26]  S. Navarra,et al.  A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study , 2016, Arthritis Research & Therapy.

[27]  T. Horiuchi,et al.  Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology , 2016, Rheumatology International.

[28]  J. Braun,et al.  Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study , 2016, Arthritis Research & Therapy.

[29]  J. Stevenson.  Clinical data and regulatory issues of biosimilar products. , 2015, The American journal of managed care.

[30]  T. Dörner,et al.  Biosimilars in rheumatology: current perspectives and lessons learnt , 2015, Nature Reviews Rheumatology.

[31]  J. Choe,et al.  A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy , 2015, Annals of the rheumatic diseases.

[32]  P. Emery,et al.  A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy , 2015, Annals of the rheumatic diseases.

[33]  G. Castañeda-Hernández,et al.  Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. , 2014, Joint, bone, spine : revue du rhumatisme.

[34]  Martina Weise,et al.  Biosimilars: the science of extrapolation. , 2014, Blood.

[35]  H. Mellstedt.  Clinical considerations for biosimilar antibodies , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[36]  P. Sarzi-Puttini,et al.  Different effects of biological drugs in rheumatoid arthritis. , 2013, Autoimmunity reviews.

[37]  C. Schneider,et al.  Setting the stage for biosimilar monoclonal antibodies , 2012, Nature Biotechnology.

[38]  J. Kay,et al.  The advent of biosimilar therapies in rheumatology—“O Brave New World” , 2012, Nature Reviews Rheumatology.

[39]  M. Kosinski,et al.  Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors , 2011, Arthritis Research & Therapy.

[40]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update , 2010, Annals of the rheumatic diseases.

[41]  J. Gómez-Reino,et al.  Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period , 2006, Arthritis research & therapy.

[42]  T. Reinke.  Why Biosimilars Can Never Be Identical To Originators-and Why They Don't Need To Be. , 2019, Managed care.

[43]  A. Herrick,et al.  Digital ulcers in systemic sclerosis , 2017, Rheumatology.

[44]  P. Sarzi-Puttini,et al.  Position paper of Italian rheumatologists on the use of biosimilar drugs. , 2015, Clinical and experimental rheumatology.

[45]  Linda Hull Felcone,et al.  Defining the difference: What Makes Biologics Unique. , 2004, Biotechnology healthcare.